Tuesday, June 02, 2026
In Detail Full day, Tuesday, June 02, 2026, Timezone: America/Chicago
Ascension must sell 7 ASCs to complete $3.9B AmSurg deal: FTC
Alan Condon / beckershospitalreview - St. Louis-based Ascension has received Federal Trade Commission approval to move forward with its planned acquisition of AmSurg — an ambulatory surgery center operator with more than 250 facilities across 34 states — but only after agreeing to divest seve…
AI Summary: The Federal Trade Commission approved Ascension’s $3.9 billion acquisition of AmSurg only after ordering divestitures of specific ambulatory surgery centers to preserve competition. Ascension must sell those ASCs before closing to prevent local market concentration and potential price hikes — because apparently somebody still has to protect patients from monopolies.
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Public Health, Long COVID, Adolescent Health, Pediatric Oncology and look for the RSS link.
StackHealth Time Machine
More StackHealth